86.94
price up icon0.92%   0.775
 
loading
Precedente Chiudi:
$86.17
Aprire:
$85.65
Volume 24 ore:
262.69K
Relative Volume:
0.15
Capitalizzazione di mercato:
$16.98B
Reddito:
$4.58B
Utile/perdita netta:
$870.87M
Rapporto P/E:
19.77
EPS:
4.3988
Flusso di cassa netto:
$945.58M
1 W Prestazione:
+1.16%
1M Prestazione:
+0.50%
6M Prestazione:
+53.10%
1 anno Prestazione:
+33.23%
Intervallo 1D:
Value
$85.55
$87.19
Intervallo di 1 settimana:
Value
$84.38
$92.86
Portata 52W:
Value
$53.56
$92.86

Incyte Corp Stock (INCY) Company Profile

Name
Nome
Incyte Corp
Name
Telefono
(302) 498-6700
Name
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
Dipendente
2,617
Name
Cinguettio
@Incyte
Name
Prossima data di guadagno
2025-02-10
Name
Ultimi documenti SEC
Name
INCY's Discussions on Twitter

Confronta INCY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
INCY
Incyte Corp
86.93 16.83B 4.58B 870.87M 945.58M 4.3988
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.11 107.45B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
478.01 64.39B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
579.00 61.13B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
847.23 52.30B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
165.59 35.49B 398.11M -1.03B -868.57M -5.7032

Incyte Corp Stock (INCY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-10-08 Downgrade Oppenheimer Outperform → Perform
2025-08-06 Aggiornamento Wells Fargo Equal Weight → Overweight
2025-08-01 Iniziato Barclays Overweight
2025-06-16 Aggiornamento Stifel Hold → Buy
2025-03-18 Downgrade Guggenheim Buy → Neutral
2025-03-18 Downgrade William Blair Outperform → Mkt Perform
2024-12-17 Iniziato UBS Neutral
2024-10-29 Aggiornamento BofA Securities Neutral → Buy
2024-10-01 Iniziato Wolfe Research Outperform
2024-09-18 Downgrade Truist Buy → Hold
2024-07-02 Downgrade BMO Capital Markets Market Perform → Underperform
2024-05-23 Iniziato Deutsche Bank Hold
2024-04-23 Iniziato Cantor Fitzgerald Neutral
2024-02-23 Iniziato Jefferies Buy
2024-02-14 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2023-12-13 Aggiornamento Leerink Partners Market Perform → Outperform
2023-12-04 Aggiornamento Guggenheim Neutral → Buy
2023-11-21 Downgrade Goldman Buy → Neutral
2023-07-25 Iniziato Citigroup Buy
2023-05-04 Downgrade BofA Securities Buy → Neutral
2023-04-10 Downgrade RBC Capital Mkts Outperform → Sector Perform
2023-03-24 Aggiornamento SVB Securities Underperform → Market Perform
2023-01-31 Iniziato Piper Sandler Overweight
2022-08-03 Downgrade Evercore ISI Outperform → In-line
2022-08-03 Downgrade Guggenheim Buy → Neutral
2022-07-28 Iniziato Wells Fargo Equal Weight
2022-02-09 Downgrade SVB Leerink Mkt Perform → Underperform
2022-01-18 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2021-11-19 Iniziato BMO Capital Markets Market Perform
2021-07-20 Aggiornamento The Benchmark Company Hold → Buy
2021-02-10 Downgrade SVB Leerink Mkt Perform → Underperform
2021-01-07 Iniziato Truist Buy
2021-01-04 Aggiornamento Guggenheim Neutral → Buy
2020-06-16 Iniziato The Benchmark Company Hold
2020-05-06 Downgrade JP Morgan Overweight → Neutral
2020-04-29 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-04-01 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2020-03-24 Ripresa William Blair Outperform
2020-03-13 Aggiornamento BofA/Merrill Neutral → Buy
2020-02-04 Ripresa BofA/Merrill Neutral
2020-01-03 Reiterato BMO Capital Markets Market Perform
2020-01-03 Downgrade Mizuho Buy → Neutral
2020-01-02 Downgrade Guggenheim Buy → Neutral
2019-10-03 Iniziato Mizuho Buy
2019-09-12 Iniziato BMO Capital Markets Market Perform
2019-09-05 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
2019-09-05 Ripresa Morgan Stanley Equal-Weight
2019-09-05 Aggiornamento Oppenheimer Perform → Outperform
2019-05-21 Iniziato Credit Suisse Neutral
2019-05-03 Downgrade Barclays Overweight → Equal Weight
2019-04-11 Iniziato Stifel Hold
2019-04-03 Downgrade RBC Capital Mkts Outperform → Sector Perform
2019-01-24 Aggiornamento William Blair Mkt Perform → Outperform
Mostra tutto

Incyte Corp Borsa (INCY) Ultime notizie

pulisher
08:55 AM

Incyte's Quarterly Earnings Preview: What You Need To Know - Barchart.com

08:55 AM
pulisher
06:07 AM

Real time alert setup for Incyte Corporation performance2025 Winners & Losers & Free Community Supported Trade Ideas - newser.com

06:07 AM
pulisher
05:03 AM

Is Incyte Corporation (ICY) stock undervalued by metricsWeekly Trend Summary & Safe Capital Investment Plans - newser.com

05:03 AM
pulisher
01:43 AM

Is Incyte Corporation (ICY) stock dividend growth reliable2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - newser.com

01:43 AM
pulisher
Oct 20, 2025

What’s next for Incyte Corporation stock priceMarket Sentiment Report & Real-Time Buy Signal Notifications - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Is Incyte Corporation (ICY) stock among top earnings plays2025 Volume Leaders & Real-Time Volume Surge Alerts - nchmf.gov.vn

Oct 20, 2025
pulisher
Oct 20, 2025

Will Incyte Corporation (ICY) stock enhance shareholder valueEarnings Growth Report & Free Fast Gain Swing Trade Alerts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Can Incyte Corporation (ICY) stock attract analyst upgradesQuarterly Earnings Summary & Weekly Watchlist for Hot Stocks - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Are You Looking for a Top Momentum Pick? Why Incyte (INCY) is a Great Choice - sharewise.com

Oct 20, 2025
pulisher
Oct 20, 2025

Multi asset correlation models including Incyte Corporation2025 Price Targets & Precise Trade Entry Recommendations - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Incyte to Report Third Quarter 2025 Financial Results on October 28 - MyChesCo

Oct 20, 2025
pulisher
Oct 20, 2025

Lobbying Update: $80,000 of INCYTE CORPORATION lobbying was just disclosed - Quiver Quantitative

Oct 20, 2025
pulisher
Oct 19, 2025

Incyte (INCY) Reports Encouraging Clinical Trial Data at ESMO Co - GuruFocus

Oct 19, 2025
pulisher
Oct 19, 2025

Incyte at ESMO Congress 2025: Strategic Focus on Tumor Programs - Investing.com

Oct 19, 2025
pulisher
Oct 19, 2025

Incyte’s cancer drug candidates show promising results in trials - Investing.com

Oct 19, 2025
pulisher
Oct 19, 2025

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma - The AI Journal

Oct 19, 2025
pulisher
Oct 18, 2025

What technical charts say about Incyte Corporation stockLong Setup & Long-Term Safe Investment Plans - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Is Incyte Corporation stock a defensive play in 20252025 Big Picture & Reliable Entry Point Trade Alerts - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Bollinger, Credo, Ambarella, Cipher, Incyte: Insider Moves Unveiled! - TipRanks

Oct 18, 2025
pulisher
Oct 17, 2025

Is Incyte Corporation (ICY) stock a defensive play amid uncertaintyWeekly Trend Summary & Real-Time Volume Trigger Notifications - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

How Incyte Corporation stock performs in rising dollar environmentMarket Performance Summary & Proven Capital Preservation Tips - newser.com

Oct 17, 2025
pulisher
Oct 17, 2025

Does Incyte Corporation show high probability of reboundMarket Activity Summary & Safe Entry Point Alerts - newser.com

Oct 17, 2025
pulisher
Oct 17, 2025

InvestingPro’s Fair Value model captures 63% gain in Incyte shares By Investing.com - Investing.com

Oct 17, 2025
pulisher
Oct 17, 2025

Will Incyte Corporation (ICY) stock see insider accumulationMarket Volume Report & Free Low Drawdown Momentum Trade Ideas - newser.com

Oct 17, 2025
pulisher
Oct 16, 2025

How Incyte Corporation stock responds to policy changesTrade Volume Report & Consistent Return Strategy Ideas - newser.com

Oct 16, 2025
pulisher
Oct 16, 2025

Incyte (INCY) Stock Is Up, What You Need To Know - Barchart.com

Oct 16, 2025
pulisher
Oct 16, 2025

Incyte Corporation stock hits 52-week high at 88.78 USD - Investing.com

Oct 16, 2025
pulisher
Oct 15, 2025

Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism - MSN

Oct 15, 2025
pulisher
Oct 15, 2025

Can Incyte Corporation rally from current levels2025 Top Gainers & Reliable Price Breakout Alerts - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Sjogren’s Syndrome Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Gilead Sciences, Incyte Corp, Novartis, GlaxoSmithKline, Janssen Research & Development, LLC - Barchart.com

Oct 15, 2025
pulisher
Oct 15, 2025

Sjogren's Syndrome Market Insights Highlight Expanding - openPR.com

Oct 15, 2025
pulisher
Oct 15, 2025

Incyte Canada Announces Health Canada approval of Opzelura® (Ruxolitinib) Cream for the Treatment of Atopic Dermatitis in Children Ages 2-11 - Yahoo

Oct 15, 2025
pulisher
Oct 15, 2025

Using Python tools to backtest Incyte Corporation strategiesMarket Movers & Fast Entry Momentum Trade Alerts - newser.com

Oct 15, 2025
pulisher
Oct 14, 2025

Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000 - The Globe and Mail

Oct 14, 2025
pulisher
Oct 14, 2025

Incyte stock price target raised to $76 from $68 at UBS on valuation By Investing.com - Investing.com South Africa

Oct 14, 2025
pulisher
Oct 14, 2025

Incyte stock price target raised to $76 from $68 at UBS on valuation - Investing.com India

Oct 14, 2025
pulisher
Oct 14, 2025

How ESMO Congress Spotlight on Early Cancer Drugs Could Influence Incyte’s (INCY) Investment Outlook - Yahoo Finance

Oct 14, 2025
pulisher
Oct 13, 2025

Incyte Corp. stock rises Monday, still underperforms market - MarketWatch

Oct 13, 2025
pulisher
Oct 13, 2025

Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025 - BioSpace

Oct 13, 2025
pulisher
Oct 13, 2025

Incyte jumps amid takeover speculation - MSN

Oct 13, 2025
pulisher
Oct 12, 2025

How Incyte Corporation stock compares to market leadersWeekly Trade Report & Weekly Hot Stock Watchlists - newser.com

Oct 12, 2025
pulisher
Oct 12, 2025

Incyte (INCY) Announces Promising Study Results for Cancer Treat - GuruFocus

Oct 12, 2025
pulisher
Oct 10, 2025

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Incyte (NASDAQ:INCY) Stock - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

RBC Capital Remains a Hold on Incyte (INCY) - The Globe and Mail

Oct 10, 2025
pulisher
Oct 09, 2025

What 14 Analyst Ratings Have To Say About Incyte - Benzinga

Oct 09, 2025
pulisher
Oct 09, 2025

Sun Pharma Attacks Incyte Patents In Alopecia Drug Battle - Law360

Oct 09, 2025
pulisher
Oct 09, 2025

INCY: JP Morgan Raises Price Target to $89, Maintains Neutral Ra - GuruFocus

Oct 09, 2025
pulisher
Oct 09, 2025

Incyte (NASDAQ:INCY) Given Hold (C+) Rating at Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Incyte Corporation $INCY Shares Purchased by Shell Asset Management Co. - MarketBeat

Oct 09, 2025

Incyte Corp Azioni (INCY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Incyte Corp Azioni (INCY) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Denton Sheila A.
EVP & General Counsel
Oct 15 '25
Sale
85.13
277
23,581
26,569
$37.38
price up icon 2.03%
$30.00
price down icon 1.82%
$107.00
price down icon 0.90%
biotechnology ONC
$318.85
price up icon 0.12%
$165.60
price down icon 1.43%
Capitalizzazione:     |  Volume (24 ore):